DYSTONIA INDUCED BY COMBINED TREATMENT WITH L-DOPA AND MK-801 IN PARKINSONIAN MONKEYS

被引：28

作者：

RUPNIAK, NMJ ^{[1
]}

BOYCE, S ^{[1
]}

STEVENTON, MJ ^{[1
]}

IVERSEN, SD ^{[1
]}

MARSDEN, CD ^{[1
]}

机构：

[1] UNIV LONDON,NATL HOSP,INST NEUROL,DEPT CLIN NEUROL,LONDON,ENGLAND

来源：

ANNALS OF NEUROLOGY | 1992年 / 32卷 / 01期

关键词：

D O I：

10.1002/ana.410320118

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We examined whether the N-methyl-D-aspartate antagonist MK-801 (dizocilpine) would reverse parkinsonism or potentiate the effects of L-dopa in primates treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In contrast to its effect in rodent models, treatment with MK-801 (0.1 mg/kg) caused bradykinesia and ataxia in parkinsonian primates, but no locomotor stimulation. Coadministration of MK-801 (0.1 mg/kg) with L-dopa (20 mg/kg) induced marked dystonia accompanied by bradykinesia and ataxia. Dystonia was not induced by either treatment given alone. These findings indicate that MK-801 should not be advocated as an adjunct to dopamine agonist therapy in Parkinson's disease.

引用

页码：103 / 105

页数：3

共 18 条

[1] PSYCHOMOTOR ACTIVITY AND COGNITIVE DISRUPTION ATTRIBUTABLE TO NMDA, BUT NOT SIGMA, INTERACTIONS IN PRIMATES [J].

BOYCE, S ;

RUPNIAK, NMJ ;

STEVENTON, MJ ;

COOK, G ;

IVERSEN, SD .

BEHAVIOURAL BRAIN RESEARCH, 1991, 42 (02) :115-121

[2] CHARACTERIZATION OF DYSKINESIAS INDUCED BY L-DOPA IN MPTP-TREATED SQUIRREL-MONKEYS [J].

BOYCE, S ;

RUPNIAK, NMJ ;

STEVENTON, MJ ;

IVERSEN, SD .

PSYCHOPHARMACOLOGY, 1990, 102 (01) :21-27

[3] ANTI-PARKINSONIAN EFFECTS OF EAA ANTAGONISTS IN THE ENTOPEDUNCULAR NUCLEUS ARE DUE TO AN ACTION AT NMDA-LIKE RECEPTORS [J].

BROTCHIE, JM ;

BEVAN, MD ;

MITCHELL, IJ ;

CROSSMAN, AR .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (03) :943-944

[4] INTERACTIONS BETWEEN GLUTAMATERGIC AND MONOAMINERGIC SYSTEMS WITHIN THE BASAL GANGLIA - IMPLICATIONS FOR SCHIZOPHRENIA AND PARKINSONS-DISEASE [J].

CARLSSON, M ;

CARLSSON, A .

TRENDS IN NEUROSCIENCES, 1990, 13 (07) :272-276

[5] THE NMDA ANTAGONIST MK-801 CAUSES MARKED LOCOMOTOR STIMULATION IN MONOAMINE-DEPLETED MICE [J].

CARLSSON, M ;

CARLSSON, A .

JOURNAL OF NEURAL TRANSMISSION, 1989, 75 (03) :221-226

[6] CENTRAL SYMPATHOMIMETIC ACTIVITY OF (+)-5-METHYL-10,11-DIHYDRO-5H-DIBENZO [A,D]CYCLOHEPTEN-5, 10-IMINE (MK-801), A SUBSTANCE WITH POTENT ANTICONVULSANT, CENTRAL SYMPATHOMIMETIC, AND APPARENT ANXIOLYTIC PROPERTIES [J].

CLINESCHMIDT, BV ;

MARTIN, GE ;

BUNTING, PR ;

PAPP, NL .

DRUG DEVELOPMENT RESEARCH, 1982, 2 (02) :135-145

[7] EFFECTS OF CLASSICAL AND NOVEL AGENTS IN A MPTP-INDUCED REVERSIBLE MODEL OF PARKINSONS-DISEASE [J].

CLOSE, SP ;

ELLIOTT, PJ ;

HAYES, AG ;

MARRIOTT, AS .

PSYCHOPHARMACOLOGY, 1990, 102 (03) :295-300

[8] LONG-TERM D1-DOPAMINE RECEPTOR SENSITIZATION IN NEONATAL 6-OHDA-LESIONED RATS IS BLOCKED BY AN NMDA ANTAGONIST [J].

CRISWELL, HE ;

MUELLER, RA ;

BREESE, GR .

BRAIN RESEARCH, 1990, 512 (02) :284-290

[9] A HYPOTHESIS ON THE PATHOPHYSIOLOGICAL MECHANISMS THAT UNDERLIE LEVODOPA-INDUCED OR DOPAMINE AGONIST-INDUCED DYSKINESIA IN PARKINSONS-DISEASE - IMPLICATIONS FOR FUTURE STRATEGIES IN TREATMENT [J].

CROSSMAN, AR .

MOVEMENT DISORDERS, 1990, 5 (02) :100-108

[10] EFFECT OF THE NMDA ANTAGONIST MK-801 ON MPTP-INDUCED PARKINSONISM IN THE MONKEY [J].

CROSSMAN, AR ;

PEGGS, D ;

BOYCE, S ;

LUQUIN, MR ;

SAMBROOK, MA .

NEUROPHARMACOLOGY, 1989, 28 (11) :1271-1273

← 1 2 →